Eligo Bioscience
Paris
About Eligo Bioscience
Eligobiotics is a developer of antibiotics intended to treat microbiome precision and bacteria-associated diseases. The company's antibiotics combine CRISPR/Cas system with engineered phage capsids, to develop antimicrobials that are used to eradicate resistant pathogens or virulent bacteria within the human microbiome, enabling clients to get next-generation antimicrobials to treat diseases caused by superbugs.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $74.7M
- Funding stage: Early Stage Venture
- Last round: Grant (May 2025)
- Website: eligo.bio
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Medical
Social Profiles
Canonical: https://fsome.com/organization/eligo-bioscience-46395 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.